![]()
(医药健闻2026年3月30日讯)全球生物制药公司优时比(UCB)宣布自研生物制剂比奇珠单抗(商品名:倍捷乐®)双适应症同日获中国国家药品监督管理局(NMPA)批准。
特别声明:以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布,本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.